PS
PeptideScholar
Reviewed Mar 2026 | Sources: PubMed

Tirzepatide vs AOD-9604: Head-to-Head Comparison

Tirzepatide is one of the most effective weight loss drugs ever developed, with FDA approval and ~20%+ weight loss in trials. AOD-9604 is an hGH fragment that failed clinical trials for obesity. The evidence gap between these two is enormous.

Side-by-Side Comparison

DimensionTirzepatideAOD-9604
Evidence LevelPhase III trials, FDA-approvedFailed Phase IIb/III trials
FDA StatusFDA-approved for T2D and obesityNot approved for any indication
MechanismDual GIP/GLP-1 receptor agonisthGH fragment (176-191) targeting fat metabolism
Weight Loss Efficacy~20-22.5% body weight lossNo significant efficacy demonstrated in trials
Side EffectsGI effects (nausea, vomiting, diarrhea)Minimal reported side effects
CostVery high (branded pharmaceutical)Low (research peptide pricing)
Evidence Level
Tirzepatide
Phase III trials, FDA-approved
AOD-9604
Failed Phase IIb/III trials
FDA Status
Tirzepatide
FDA-approved for T2D and obesity
AOD-9604
Not approved for any indication
Mechanism
Tirzepatide
Dual GIP/GLP-1 receptor agonist
AOD-9604
hGH fragment (176-191) targeting fat metabolism
Weight Loss Efficacy
Tirzepatide
~20-22.5% body weight loss
AOD-9604
No significant efficacy demonstrated in trials
Side Effects
Tirzepatide
GI effects (nausea, vomiting, diarrhea)
AOD-9604
Minimal reported side effects
Cost
Tirzepatide
Very high (branded pharmaceutical)
AOD-9604
Low (research peptide pricing)

Peptide Overviews

Tirzepatide

AFDA Approved

Tirzepatide is the first dual GIP and GLP-1 receptor agonist, approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Achieves unprecedented weight loss in clinical trials.

Weight LossFDA Approved
View full Tirzepatide profile →

AOD-9604

CPreclinical

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) originally developed for obesity treatment. It received GRAS status from the FDA for use in food products.

Weight LossNot Approved
View full AOD-9604 profile →

Tirzepatide vs AOD-9604: FAQ

Stay Informed on Peptide Research

Get weekly comparison updates, new study alerts, and regulatory changes.

No spam. Unsubscribe anytime.

Medical Disclaimer

This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.

No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.